Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 13.8% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares dropped 13.8% during trading on Tuesday . The company traded as low as $0.15 and last traded at $0.17. Approximately 73,990,631 shares traded hands during trading, a decline of 35% from the average daily volume of 113,742,805 shares. The stock had previously closed at $0.19.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research report on Sunday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Trading Down 25.0 %

The business has a 50 day moving average price of $0.60 and a 200 day moving average price of $0.37. The company has a market capitalization of $2.10 billion, a P/E ratio of -0.21 and a beta of 2.07. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC purchased a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals as of its most recent SEC filing. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.